Morepen Laboratories Limited ( (IN:MOREPENLAB) ) just unveiled an update.
Morepen Laboratories Limited has secured approval from China’s National Medical Products Administration for exporting Loratadine, an anti-allergy API, marking a strategic entry into the Chinese pharmaceutical market. This approval not only strengthens Morepen’s position as a dominant global manufacturer of Loratadine but also opens up significant growth opportunities in China, reinforcing its leadership in the global healthcare industry.
More about Morepen Laboratories Limited
Morepen Laboratories Limited is a global leader in Active Pharmaceutical Ingredient (API) manufacturing, particularly known for its dominance in the US generics market for Loratadine. The company exports to 82 countries and holds a significant market share in several leading products such as Montelukast, Desloratadine, Atorvastatin, Rosuvastatin, and Fexofenadine. With USFDA-approved manufacturing facilities, Morepen continues to expand its presence in regulated and emerging markets worldwide.
YTD Price Performance: -39.62%
Average Trading Volume: 520,512
Current Market Cap: 26.22B INR
Learn more about MOREPENLAB stock on TipRanks’ Stock Analysis page.